Frederik van Delft

Frederik van Delft

Auto-generated profile, based on publicly available information

Frederik van Delft

Newcastle Hospitals NHS Foundation Trust, Newcastle, UK

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 December 2010 in Nature
Verified
Journal Article
Closed access
KAKristina Anderson
Kristina Anderson
CLChristoph Lutz
Christoph Lutz
FDFrederik W. van Delft
Frederik W. van Delft
CBCaroline M. Bateman
Caroline M. Bateman
YGYanping Guo
Yanping Guo
MGMel Greaves
Mel Greaves

12 January 2014 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
EPElli Papaemmanuil
Elli Papaemmanuil
IRInmaculada Rapado
Inmaculada Rapado
YLYilong Li
Yilong Li
NPNicola E Potter
Nicola E Potter
DWDavid Wedge
David Wedge
PCPeter J Campbell
Peter J Campbell

3 September 2015 in Blood
Verified
Journal Article
Closed access
PDF file
KTKiran Tawana
Kiran Tawana
JWJun Wang
Jun Wang
ARAline Renneville
Aline Renneville
CBCsaba Bödör
Csaba Bödör
RHRobert Hills
Robert Hills
JFJude Fitzgibbon
Jude Fitzgibbon
In-depth molecular investigation of familial leukemia has been limited by the rarity of recognized cases. This study examines the genetic events initiating leukemia and details the clinical progression of disease across multiple families harboring germ-line CEBPA mutations. Clinical data were collected from 10 CEBPA-mutated families, representing 24 members with acute myeloid leukemia (AML). Whole-exome (WES) and deep sequencing were performed to genetically profile tumors and define patterns of clonal evolution. Germline CEBPA mutations clustered within the N-terminal and were highly penetrant, with AML presenting at a median age of 24.5 years (range, 1.75-46 years). In all diagnostic tumors tested (n = 18), double CEBPA mutations (CEBPAdm) were detected, with acquired (somatic) mutations preferentially targeting the C-terminal. Somatic CEBPA mutations were unstable throughout the disease course, with different mutations identified at recurrence. Deep sequencing of diagnostic and relapse paired samples confirmed that relapse-associated CEBPA mutations were absent at diagnosis, suggesting recurrence was triggered by novel, independent clones. Integrated WES and deep sequencing subsequently revealed an entirely new complement of mutations at relapse, verifying the presentation of a de novo leukemic episode. The cumulative incidence of relapse in familial AML was 56% at 10 years (n = 11), and 3 patients experienced ≥3 disease episodes over a period of 17 to 20 years. Durable responses to secondary therapies were observed, with prolonged median survival after relapse (8 years) and long-term overall survival (10-year overall survival, 67%). Our data reveal that familial CEBPA-mutated AML exhibits a unique model of disease progression, associated with favorable long-term outcomes. Key Points Germ-line CEBPA mutations are highly penetrant, causing early-onset de novo AML associated with favorable survival outcomes. Familial CEBPA-mutated AML displays a unique model of disease progression, with recurrence caused by novel, independent leukemic episodes.

23 May 2006 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
JSJonathan Strefford
Jonathan Strefford
FDFrederik W. van Delft
Frederik W. van Delft
HRHazel M. Robinson
Hazel M. Robinson
HWHelen Worley
Helen Worley
OYOlga Yiannikouris
Olga Yiannikouris
CHChristine J. Harrison
Christine J. Harrison
We have previously identified a unique subtype of acute lymphoblastic leukemia (ALL) associated with a poor outcome and characterized by intrachromosomal amplification of chromosome 21 including theRUNX1gene (iAMP21). In this study, array-based comparative genomic hybridization (aCGH) (n= 10) detected a common region of amplification (CRA) between 33.192 and 39.796 Mb and a common region of deletion (CRD) between 43.7 and 47 Mb in 100% and 70% of iAMP21 patients, respectively. High-resolution genotypic analysis (n= 3) identified allelic imbalances in the CRA. Supervised gene expression analysis showed a distinct signature for eight patients with iAMP21, with 10% of overexpressed genes located within the CRA. The mean expression of these genes was significantly higher in iAMP21 when compared to other ALL samples (n= 45). Although genomic copy number correlated with overall gene expression levels within areas of loss or gain, there was considerable individual variation. A unique subset of differentially expressed genes, outside the CRA and CRD, were identified when gene expression signatures of iAMP21 were compared to ALL samples withETV6-RUNX1fusion (n= 21) or high hyperdiploidy with additional chromosomes 21 (n= 23). From this analysis,LGMNwas shown to be overexpressed in patients with iAMP21 (P= 0.0012). Genomic and expression data has further characterized this ALL subtype, demonstrating high levels of 21q instability in these patients leading to proposals for mechanisms underlying this clinical phenotype and plausible alternative treatments.

9 June 2011 in Blood
Verified
Journal Article
Closed access
PDF file
FDFrederik W. van Delft
Frederik W. van Delft
SHSharon Horsley
Sharon Horsley
SCSue Colman
Sue Colman
KAKristina Anderson
Kristina Anderson
CBCaroline Bateman
Caroline Bateman
MGMel Greaves
Mel Greaves
B-cell precursor childhood acute lymphoblastic leukemia with ETV6-RUNX1 (TEL-AML1) fusion has an overall good prognosis, but relapses occur, usually after cessation of treatment and occasionally many years later. We have investigated the clonal origins of relapse by comparing the profiles of genomewide copy number alterations at presentation in 21 patients with those in matched relapse (12-119 months). We identified, in total, 159 copy number alterations at presentation and 231 at relapse (excluding Ig/TCR). Deletions of CDKN2A/B or CCNC (6q16.2-3) or both increased from 38% at presentation to 76% in relapse, suggesting that cell-cycle deregulation contributed to emergence of relapse. A novel observation was recurrent gain of chromosome 16 (2 patients at presentation, 4 at relapse) and deletion of plasmocytoma variant translocation 1 in 3 patients. The data indicate that, irrespective of time to relapse, the relapse clone was derived from either a major or minor clone at presentation. Backtracking analysis by FISH identified a minor subclone at diagnosis whose genotype matched that observed in relapse ∼ 10 years later. These data indicate subclonal diversity at diagnosis, providing a variable basis for intraclonal origins of relapse and extended periods (years) of dormancy, possibly by quiescence, for stem cells in ETV6-RUNX1+ acute lymphoblastic leukemia.

17 November 2011 in Blood
Verified
Journal Article
Closed access
PDF file
GCGiovanni Cazzaniga
Giovanni Cazzaniga
FDFrederik W. van Delft
Frederik W. van Delft
Luca Lo NigroLuca Lo Nigro
Luca Lo Nigro
AFAnthony M. Ford
Anthony M. Ford
JSJoannah Score
Joannah Score
MGMel Greaves
Mel Greaves
The timing and developmental sequence of events for BCR-ABL1+ acute lymphoblastic leukemia (ALL), usually associated with IKAROS (IKZF1) deletions, are unknown. We assessed the status of BCR-ABL1 and IKZF1 genes in 2 pairs of monozygotic twins, one pair concordant, the other discordant for Philadelphia chromosome positive (Ph+) ALL. The twin pair concordant for ALL shared identical BCR-ABL1 genomic sequence indicative of monoclonal, in utero origin. One twin had IKZF1 deletion and died after transplantation. The other twin had hyperdiploidy, no IKZF1 deletion, and is still in remission 8 years after transplantation. In the twin pair discordant for ALL, neonatal blood spots from both twins harbored the same clonotypic BCR-ABL1 sequence. Low level BCR-ABL1+ cells were present in the healthy co-twin but lacked the IKZF1 deletion present in the other twin9s leukemic cells. The twin with ALL relapsed and died after transplantation. The co-twin remains healthy and leukemia free. These data show that in childhood Ph+ ALL, BCR-ABL1 gene fusion can be a prenatal and possibly initiating genetic event. In the absence of additional, secondary changes, the leukemic clone remains clinically silent. IKZF1 is a secondary and probable postnatal mutation in these cases, and as a recurrent but alternative copy number change is associated with poor prognosis.